TRENDING :  Market Movers  |  Top 50   SPY (0.23%)    TSLA (-2.49%)    CANF (1.36%)    BYND (-2.96%)    BTCUSD (%)    ONCS (-3.12%)    AMZN (0.43%)    TVIX (-4.25%)    VXX (-2.07%)    ROKU (6.45%)    ACAD (2.45%)    OIH (-1.43%)    MCHP (-1.44%)    MAXR (-13.79%)    KSS (-0.06%)    IRBT (0.03%)    IP (-0.24%)    INTC (0.09%)    GDX (0.64%)    FTNT (0.33%)    ECOR (-4.53%)    DIS (0.05%)    DFRG (2.06%)    CMG (-0.69%)    BIOC (9.74%)

 VKTX - Viking Therapeutics

$8.54 [0.2][2.4%]

Next Earnings

8/8/2019

AMC

Recommend
Trade Idea »



ANALYST RATINGS

Quarterly Rating Chart
Rating

NaN


1=Strong Buy, 2=Buy, 3=Hold, 4=Underperform, 5=Sell
Price Targets
High $40.00
Low $40.00
Average $40.00
Current $8.54

CompanyAnalyst NamePT ActionActionRatingTargetDate
Raymond JamesLowersMaintains$40.0003/14/19
*Last 90 days

OPEN RECOMMENDATIONS

No recommendations found.


This list is limited to recommendations made in last 7 days only. Subscribe to a service to see all their recommendations.

TRADERS TRACKING $VKTX

TRENDING ARTICLES



3 Small-Cap Biotech Stocks You Can Buy Right Now

05/17/19
Few stocks have the potential to generate explosive returns like small cap biotech stocks Week in and week out small cap biotechs report pipeline updates that often send their shares into orbit There are too many small cap biotech stocks to easily keep track of though And not all

Viking Therapeutics Inc (VKTX) Q1 2019 Earnings Call Transcript

05/03/19
Image source The Motley Fool Viking Therapeutics Inc NASDAQ VKTX Q1 160 2019 Earnings Call May 02 2019 4 30 p m ET Contents Prepared Remarks Questions and Answers Call Participants Prepared Remarks Operator

2 Reasons Gilead Sciences' NASH Program Could Bounce Back

04/27/19
Around 20 million Americans are at risk of liver failure thanks to a poorly understood epidemic sweeping the nation and many don t even know it Non alcoholic steatohepatitis NASH is a huge problem and drugmakers big and small are racing with each other to develop the first